LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Merck & Co Inc.

Cerrado

SectorSalud

75.99 1.7

Resumen

Variación precio

24h

Actual

Mínimo

74.35

Máximo

76.16

Métricas clave

By Trading Economics

Ingresos

1.3B

5.1B

Ventas

-95M

16B

P/B

Media del Sector

11.69

56.602

BPA

2.22

Rentabilidad por dividendo

4.26

Margen de beneficio

32.745

Empleados

73,000

EBITDA

386M

7.3B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+38.51% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

4.26%

2.45%

Próximas Ganancias

29 jul 2025

Fecha Próximo Dividendo

7 jul 2025

Próxima Fecha de Ex Dividendo

16 jun 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-11B

202B

Apertura anterior

74.29

Cierre anterior

75.99

Noticias sobre sentimiento de mercado

By Acuity

45%

55%

161 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Merck & Co Inc. Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 abr 2025, 18:18 UTC

Principales Movimientos del Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 abr 2025, 09:39 UTC

Principales Movimientos del Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 feb 2025, 12:33 UTC

Ganancias

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 feb 2025, 11:57 UTC

Ganancias

Merck 4Q Sales Increase Results in Swing to Profit

12 may 2025, 17:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

29 abr 2025, 09:30 UTC

Principales Noticias

Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug -- WSJ

27 abr 2025, 11:00 UTC

Principales Noticias

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 abr 2025, 20:08 UTC

Ganancias

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 abr 2025, 16:05 UTC

Principales Noticias
Ganancias

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 abr 2025, 14:36 UTC

Charlas de Mercado
Ganancias

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 abr 2025, 14:10 UTC

Charlas de Mercado
Ganancias

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 abr 2025, 11:35 UTC

Ganancias

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 abr 2025, 10:58 UTC

Principales Noticias
Ganancias

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 abr 2025, 10:55 UTC

Ganancias

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 abr 2025, 10:31 UTC

Ganancias

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Keytruda Sales $7.21B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Keytruda Sales Up 4% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 abr 2025, 10:30 UTC

Ganancias

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 abr 2025, 09:13 UTC

Acciones populares

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mar 2025, 05:00 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mar 2025, 19:42 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mar 2025, 10:30 UTC

Principales Noticias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 feb 2025, 14:48 UTC

Ganancias

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 feb 2025, 11:51 UTC

Ganancias

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 feb 2025, 11:50 UTC

Ganancias

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

Comparación entre iguales

Cambio de precio

Merck & Co Inc. Esperado

Precio Objetivo

By TipRanks

38.51% repunte

Estimación a 12 meses

Media 101.76 USD  38.51%

Máximo 138 USD

Mínimo 82 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Merck & Co Inc. Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

9

Comprar

8

Mantener

0

Vender

Puntuación técnica

By Trading Central

76.03 / 83.28Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

161 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.